28/08/2014 01:24:30 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
08/27/20144:40PMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Wednesday's session are Express Inc. (EXPR), Michaels Cos. (MIK) and Smith & Wesson Holding Corp. (SWHC). Brown Shoe Co. (BWS) said its fiscal second-quarter profit rose 18% as its wholesale business and Famous Footwear chain reported higher sales. The company's... More...>>
08/27/20145:00AMBWEuropean Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of C...
Daklinza, when used in combination with sofosbuvir, is an all-oral, once daily regimen that yields cure rates of up to 100% Daklinza + sofosbuvir offers potential cure for a broad range of EU HCV patients, including those with advanced liver disease, genotype 3 and protease inhibitor failures Bristol-Myers Squibb Company (NYSE:BMY... More...>>
08/21/20141:31PMBWU.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE), & for the Red...
Eliquis demonstrated noninferiority in the primary efficacy endpoint of recurrent symptomatic venous thromboembolism (VTE) or VTE-related death versus enoxaparin/warfarin in the AMPLIFY trial Eliquis demonstrated superiority in the primary safety endpoint of major bleeding versus enoxaparin/warfarin in the AMPLIFY trial... More...>>
08/20/20148:00AMBWBristol-Myers Squibb & Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy & Chemotherapy Combination Re...
Phase I study to evaluate OPDIVO (nivolumab), Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with Celgene’s ABRAXANE® for multiple cancers Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq:CELG) announced today the establishment of a clinical trial collaboration to evaluate... More...>>
08/20/20148:00AMBWBristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014
Fourteen abstracts to be presented, including new analyses from the ARISTOTLE®, AMPLIFY® and AMPLIFY-EXT trials evaluating patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world... More...>>
08/07/201411:00AMPRNUSLeica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnost...
Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnostics that Support Targeted Therapies PR Newswire NUSSLOCH, Germany, August 7, 2014 NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ -- Leica Biosystems announces a collaboration with Bristol-Myers Squibb... More...>>
08/07/201411:00AMPRNUSLeica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnost...
Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnostics that Support Targeted Therapies PR Newswire NUSSLOCH, Germany, August 7, 2014 NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ -- Leica Biosystems announces a collaboration with Bristol-Myers Squibb... More...>>
08/04/20145:44AMDJNAllied Minds Forms University Research Venture with Bristol-Myers
LONDON--Science and technology commercialization company Allied Minds PLC (ALM.LN) Monday announced the formation of a joint venture with Bristol-Myers Squibb Co. (BMY) for research and development of biopharmaceutical innovations from U.S. university research institutions. -Write to Rory Gallivan at rory.gallivan@wsj.com;... More...>>
08/04/20142:00AMBWAllied Minds & Bristol-Myers Squibb Form New Enterprise to Advance Discoveries of Biopharmaceutical Innovations at Leading U....
Allied-Bristol Life Sciences LLC to identify and speed development of promising science and technologies Unique collaboration focused on transforming early-stage academic innovation to therapeutic candidates for clinical study Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the formation... More...>>
07/29/20147:00AMBWEuropean Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE), & ...
In the AMPLIFY trial, Eliquis was shown to be non-inferior for the treatment of recurrent venous thromboembolism (VTE)/VTE-related death and was statistically superior in the primary safety endpoint of major bleeding vs. enoxaparin/warfarin In the AMPLIFY-EXT trial, Eliquis demonstrated a superior reduction in VTE/all-cause... More...>>
07/24/20144:01PMPRNUSBioMed Realty And Bristol-Myers Squibb Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park I...
BioMed Realty And Bristol-Myers Squibb Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park In Redwood City, California Global BioPharmaceutical Leader Leases an Additional 61,000 Square Feet to Grow Its Presence and Research Capabilities in the Bay Area PR Newswire SAN DIEGO, July 24, 2014... More...>>
07/24/201410:11AMDJNBristol-Myers Posts Lower Profit, Revenue -- Update
By Joshua Jamerson Bristol-Myers Squibb Co. reported declines in second-quarter earnings and revenue as the drug maker continues to restructure its operations. Results, though, surpassed analyst expectations, helped by strong sales of the company's cancer drugs. Bristol shares slipped 25 cents to $49.07 in morning trading... More...>>
07/24/20147:30AMBWBristol-Myers Squibb Reports Second Quarter 2014 Financial Results
Posts Second Quarter GAAP EPS of $0.20 and Non-GAAP EPS of $0.48 Achieves Important Regulatory Milestones across Portfolio Approval for Daklinza+Sunvepra Dual Regimen in Japan Positive Advisory Opinions for Daklinza and Eliquis in Europe Plans for Third Quarter Submission of a Biologics License Application in the U.S... More...>>
07/23/20149:00PMBWBristol-Myers Squibb & Ono Pharmaceutical Co., Ltd. Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea & ...
Companies to develop and commercialize Opdivo (nivolumab), Yervoy (ipilimumab), and three early–stage clinical immuno-oncology assets as single agents and combination regimens Bristol-Myers Squibb gains access to Opdivo in Japan, South Korea and Taiwan, broadening company’s leadership in immuno-oncology Ono strengthens... More...>>
07/17/20148:06AMBWBristol-Myers Squibb & Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness & Safety...
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) assessing the effectiveness and safety... More...>>
07/10/201412:36PMBWBristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab)...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), the company is planning a third quarter submission of a Biologics Licensing Application (BLA) for Opdivo® (nivolumab) for previously treated advanced melanoma. This will mark the second... More...>>
07/10/20147:30AMBWBristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab)...
Bristol-Myers Squibb Company (NYSE:BMS) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), the company is planning a third quarter submission of a Biologics Licensing Application (BLA) for Opdivo® (nivolumab) for previously treated advanced melanoma. This will mark the second... More...>>
07/07/20143:20PMDJNNovartis Wins 'Breakthrough' Status for Leukemia Treatment
ZURICH-- Novartis AG said Monday the U.S. Food and Drug Administration designated a new leukemia treatment it is developing as a "breakthrough" therapy, giving it access to a potentially faster regulatory review process. Basel-based Novartis's CTL019 treatment, which is being tested at the University of Pennsylvania's... More...>>
07/07/20149:00AMDJNU.S. Hot Stocks: Hot Stocks To Watch
Among the companies with shares expected to actively trade in Monday's session are BioDelivery Sciences International Inc. (BDSI), CASI Pharmaceuticals Inc. (CASI) and PetSmart Inc. (PETM). A pain drug developed by Endo Pharmaceuticals PLC and BioDelivery Sciences met its primary endpoint in a Phase 3 study, the companies... More...>>
07/07/20147:00AMBWJapan Approves First All-Oral, Interferon- & Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) & Sunvepra® (asu...
Offers new treatment option for genotype 1 HCV patients in Japan who are interferon-ineligible/intolerant, or did not previously respond to treatment Japanese HCV patients in urgent need of care now have opportunity for cure, including older patients and those with compensated cirrhosis Bristol-Myers Squibb Company (NYSE:BMY... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy140828 01:24